Aura Biosciences Inc (AURA) Price & Analysis

Compare

279 Followers

AURA Stock Chart & Stats

$6.60

-$0.11(-1.36%)

At close: Jan 08 4:00 PM EST

$6.60

-$0.11(-1.36%)

Day’s Range― - ―

52-Week Range$4.35 - $9.53

Previous CloseN/A

Volume82.15K

Average Volume (3M)302.40K

Market Cap

$352.84M

Enterprise Value$203.98M

Total Cash (Recent Filing)$161.87M

Total Debt (Recent Filing)$17.75M

Price to Earnings (P/E)―

Beta2.11

Next Earnings

Mar 31, 2026

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding62,119,873

10 Day Avg. Volume325,525

30 Day Avg. Volume302,397

Financial Highlights & Ratios

PEG Ratio0.50

Price to Book (P/B)2.69

Price to Sales (P/S)0.00

P/FCF Ratio-5.03

Enterprise Value/Market Cap0.58

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-228.93

Enterprise Value/Ebitda-1.91

Forecast

1Y Price Target

$19.33

Price Target Upside192.88% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trials ProgressAura Biosciences is advancing bel-sar for two additional ocular oncology indications, highlighting a potential ocular oncology franchise the company may tap into.

Market PotentialAura estimates their three ocular indications represent over 60,000 annual cases in the United States and Europe, indicating a substantial market potential.

Regulatory ApprovalsBel-sar has been granted Orphan Drug Designation from the FDA and EMA as well as Fast Track designation for treatment of early choroidal melanoma, which are signals of continued regulatory and clinical alignment.

Bears Say

Financial ConstraintsAura Biosciences has approximately 1.5 years of cash left, indicating potential financial constraints in the near future.

Market CompetitionNMIBC is getting quite crowded in later/more high-risk settings already, and even uveal melanoma has a strong contender in slightly larger tumors.

Aura Biosciences Inc News

Aura Biosciences re-initiated with an Outperform at Evercore ISI

Evercore ISI re-initiated coverage of Aura Biosciences (AURA) with an Outperform rating and $13 price target Aura uses...

5d ago

AURA

Aura Biosciences reports Q3 EPS (40c), consensus (47c)

“In the third quarter, we remained focused on clinical execution in both our global Phase 3 CoMpass trial...

17d ago

AURA

Aura Biosciences announces cash to fund operations into 1H of 2027

As of September 30, 2025, the Company had cash and cash equivalents and marketable securities totaling $161.9 million....

17d ago

AURA

Innovative Approach and Promising Data Drive Buy Rating for Aura Biosciences

Evercore ISI analyst Jonathan Miller has maintained their bullish stance on AURA stock, giving a Buy rating on...

5d ago

AURA

Buy Rating on Aura Biosciences Inc. Driven by Promising Pipeline and Strategic Expansion in Ocular Oncology

Analyst Oliver McCammon of LifeSci Capital maintained a Buy rating on Aura Biosciences Inc, with a price target...

16d ago

AURA

Aura Biosciences Reports Q3 2025 Financial Results

Aura Biosciences Inc ( ($AURA) ) has released its Q3 earnings. Here is a breakdown of the information...

16d ago

AURA

Positive Outlook for Aura Biosciences Inc: Strong Financial Position and Promising Clinical Progress Justify Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on AURA stock, giving a Buy rating today....

17d ago

AURA

Aura Biosciences Inc: Strong Buy Rating Backed by Promising Clinical Progress and Strategic Oncology Expansion

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Aura Biosciences...

17d ago

AURA

Aura Biosciences Reports Q3 2025 Financial Results

Aura Biosciences Inc ( ($AURA) ) has issued an update. On November 13, 2025, Aura Biosciences reported its...

17d ago

AURA

Aura Biosciences Advances Bladder Cancer Treatment with AU-011 Study

Aura Biosciences Inc (($AURA)) announced an update on their ongoing clinical study. Aura Biosciences Inc. is conducting a...

1M ago

AURA

Aura Biosciences Advances Eye Cancer Treatment with Phase 2 Trial Update

Aura Biosciences Inc (($AURA)) announced an update on their ongoing clinical study. Aura Biosciences Inc. is conducting a...

1M ago

AURA

Aura Biosciences’ Phase 3 Trial: A Potential Game-Changer in Ocular Melanoma Treatment

Aura Biosciences Inc (($AURA)) announced an update on their ongoing clinical study. Aura Biosciences Inc (AURA) is conducting...

1M ago

AURA

Optimistic Buy Rating for Aura Biosciences Inc: Promising Pipeline, Strategic Positioning, and Strong Financials

Leerink Partners analyst Andrew Berens maintained a Buy rating on Aura Biosciences Inc on August 13 and set...

4M ago

AURA

Aura Biosciences reports Q2 EPS (47c) vs (41c) last year

“We continued to focus on execution in our clinical programs in the second quarter, including our ongoing global...

4M ago

AURA

AURA FAQ

What was Aura Biosciences Inc’s price range in the past 12 months?

Aura Biosciences Inc lowest stock price was $4.34 and its highest was $9.53 in the past 12 months.

What is Aura Biosciences Inc’s market cap?

Aura Biosciences Inc’s market cap is $352.84M.

When is Aura Biosciences Inc’s upcoming earnings report date?

Aura Biosciences Inc’s upcoming earnings report date is Mar 31, 2026 which is in 121 days.

How were Aura Biosciences Inc’s earnings last quarter?

Aura Biosciences Inc released its earnings results on Nov 13, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.464 by $0.064.

Is Aura Biosciences Inc overvalued?

According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aura Biosciences Inc pay dividends?

Aura Biosciences Inc does not currently pay dividends.

What is Aura Biosciences Inc’s EPS estimate?

Aura Biosciences Inc’s EPS estimate is -0.43.

How many shares outstanding does Aura Biosciences Inc have?

Aura Biosciences Inc has 62,119,873 shares outstanding.

What happened to Aura Biosciences Inc’s price movement after its last earnings report?

Aura Biosciences Inc reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.464. Following the earnings report the stock price went down -0.718%.

Which hedge fund is a major shareholder of Aura Biosciences Inc?

Currently, no hedge funds are holding shares in AURA

Aura Biosciences Inc Stock Smart Score

Underperform

Fundamentals

Return on Equity

-64.26%

Trailing 12-Months

Asset Growth

-6.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aura Biosciences Inc

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Aura Biosciences Inc (AURA) Earnings & Revenues

Historic Earnings Reports

AURA Stock 12 Month Forecast

Average Price Target

$19.33

▲(192.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","14":"$14","19":"$19","24":"$24"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9,14,19,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.13,7.427692307692308,8.725384615384616,10.023076923076923,11.32076923076923,12.618461538461538,13.916153846153847,15.213846153846152,16.51153846153846,17.80923076923077,19.106923076923078,20.404615384615383,21.70230769230769,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.13,7.145384615384615,8.16076923076923,9.176153846153845,10.19153846153846,11.206923076923076,12.222307692307691,13.237692307692306,14.253076923076922,15.268461538461537,16.283846153846152,17.299230769230768,18.314615384615383,{"y":19.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.13,6.658461538461538,7.186923076923077,7.715384615384615,8.243846153846153,8.772307692307692,9.30076923076923,9.829230769230769,10.357692307692307,10.886153846153846,11.414615384615384,11.943076923076923,12.471538461538461,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.31,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.13,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >